These lesions drive carcinogenesis by disrupting cell cycle checkpoints, suppressing apoptosis, and promoting oncogenic activation (e.g., KRAS, PI3K) while silencing tumor suppressors (e.g., TP53, BRCA1), collectively fostering a pro-tumorigenic microenvironment 39-42. Here, TP53 is linked to neoplasm.